CGRP Forum is made possible thanks to support from AbbVie, Lilly, Organon and Pfizer, all of whom have no influence or control of editorial content. More information is available here »
In December 2019, Ubrelvy (ubrogepant) became the first oral CGRP receptor antagonist (gepant) to be approved for the acute treatment of migraine in adults. Approval was supported by data including the results of two Phase 3 clinical trials, ACHIEVE 1 and 2 of ubrogepant in the acute treatment of migraine. A Phase 1 trial demonstrated the tolerability and safety of intermittent, high frequency dosing of ubrogepant.
This program is funded in part via an independent educational grant from AbbVie.
Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.
Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.
